{"id":"rd","safety":{"commonSideEffects":[{"rate":null,"effect":"Tumor lysis syndrome"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Gastrointestinal toxicity"}]},"_chembl":null,"_dailymed":{"setId":"253ef0d8-3f62-4614-ad7d-df877d7680d1","title":"STARFIRE RED DANIO (STARFIRE RED DANIO TRANSGENIC WHOLE (RZF2005 RDNA CONSTRUCTS)) NOT APPLICABLE [GLOFISH LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rd (likely referring to a BCL-2 inhibitor in development by Ascentage Pharma) works by inhibiting anti-apoptotic BCL-2 family proteins, allowing pro-apoptotic signals to proceed and trigger programmed cell death in malignant cells. This mechanism is particularly relevant in hematologic malignancies where BCL-2 overexpression drives survival of cancer cells.","oneSentence":"Rd is a BCL-2 family protein inhibitor that promotes apoptosis in cancer cells by blocking anti-apoptotic proteins.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T05:25:58.591Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hematologic malignancies (specific indications pending confirmation)"}]},"trialDetails":[{"nctId":"NCT05789030","phase":"NA","title":"Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2022-07-01","conditions":"Autoimmune Diseases","enrollment":60},{"nctId":"NCT07477587","phase":"PHASE1","title":"A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-05-27","conditions":"Multiple Myeloma (MM)","enrollment":258},{"nctId":"NCT04923893","phase":"PHASE3","title":"A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-08-19","conditions":"Multiple Myeloma","enrollment":743},{"nctId":"NCT04656951","phase":"PHASE2","title":"Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cologne","startDate":"2021-06-01","conditions":"Multiple Myeloma","enrollment":67},{"nctId":"NCT07069595","phase":"PHASE2","title":"PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-02-26","conditions":"Breast Cancer, Residual Disease, Triple Negative Breast Cancer (TNBC)","enrollment":78},{"nctId":"NCT07223177","phase":"NA","title":"Philips FAST SpO2 Technology With Masimo Sensors for SpO2 Monitoring in the Neonatal, Infant, and Pediatric Populations","status":"RECRUITING","sponsor":"Masimo Corporation","startDate":"2025-12-17","conditions":"SpO2","enrollment":100},{"nctId":"NCT05765812","phase":"PHASE1, PHASE2","title":"A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"Debiopharm International SA","startDate":"2023-05-15","conditions":"Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III","enrollment":116},{"nctId":"NCT06969430","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"Debiopharm International SA","startDate":"2025-05-30","conditions":"Acute Myeloid Leukemia","enrollment":134},{"nctId":"NCT05332613","phase":"NA","title":"Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2022-04-27","conditions":"Non-Alcoholic Fatty Liver Disease","enrollment":40},{"nctId":"NCT04362007","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2020-07-14","conditions":"Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)","enrollment":8},{"nctId":"NCT07426900","phase":"NA","title":"Effects of Thoracolumbar Stabilization Versus Spinal Decompression Exercises on Maigne's Syndrome","status":"COMPLETED","sponsor":"Riphah International University","startDate":"2025-01-01","conditions":"Syndrome, Manganese Neurotoxicity","enrollment":26},{"nctId":"NCT02264678","phase":"PHASE1, PHASE2","title":"Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2014-10-31","conditions":"Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer","enrollment":357},{"nctId":"NCT07123103","phase":"PHASE1","title":"A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Exelixis","startDate":"2025-08-18","conditions":"Solid Tumors","enrollment":150},{"nctId":"NCT07416032","phase":"EARLY_PHASE1","title":"A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-02-20","conditions":"Immune Thrombocytopenia (ITP)","enrollment":27},{"nctId":"NCT07061938","phase":"PHASE1, PHASE2","title":"Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease","status":"RECRUITING","sponsor":"Acepodia Biotech, Inc.","startDate":"2026-01-01","conditions":"IgG4 Related Disease","enrollment":30},{"nctId":"NCT06191666","phase":"NA","title":"BfedBwell Proof-of-Concept Pilot","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2024-02-05","conditions":"Cancer Survivorship, Obesity, Overweight","enrollment":20},{"nctId":"NCT07404150","phase":"","title":"Women, Weight, and Well-being","status":"ENROLLING_BY_INVITATION","sponsor":"Heather Conradson","startDate":"2026-01-12","conditions":"Obesity and Cardiovascular Risk","enrollment":60},{"nctId":"NCT07025330","phase":"PHASE2","title":"A Study of Efgartigimod in Patients With IgG4-Related Disease","status":"RECRUITING","sponsor":"Stanford University","startDate":"2025-11-12","conditions":"IgG4-related Disease","enrollment":5},{"nctId":"NCT06625112","phase":"","title":"A Multicentric European Study to Promote Clinical Trial Readiness for STXBP1-related Disorders","status":"RECRUITING","sponsor":"European STXBP1 Consortium","startDate":"2025-11-04","conditions":"STXBP1 Encephalopathy With Epilepsy","enrollment":120},{"nctId":"NCT04918147","phase":"PHASE2","title":"Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-10-13","conditions":"IgG4 Related Disease, IgG4-RD","enrollment":8},{"nctId":"NCT05662241","phase":"PHASE3","title":"A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zenas BioPharma (USA), LLC","startDate":"2023-01-09","conditions":"IgG4 Related Disease","enrollment":194},{"nctId":"NCT06432881","phase":"NA","title":"Investigation of Skin Pigmentation Effect on Performance of Masimo Pulse Oximetry (INSPIRE)","status":"RECRUITING","sponsor":"Masimo Corporation","startDate":"2024-01-08","conditions":"Hypoxemia","enrollment":152},{"nctId":"NCT06854653","phase":"PHASE2","title":"A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL","status":"RECRUITING","sponsor":"Prescient Therapeutics, Ltd.","startDate":"2025-03-28","conditions":"CTCL","enrollment":115},{"nctId":"NCT04835805","phase":"PHASE1","title":"A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2021-05-13","conditions":"Melanoma","enrollment":65},{"nctId":"NCT06935474","phase":"PHASE1, PHASE2","title":"C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease","status":"NOT_YET_RECRUITING","sponsor":"AbelZeta Inc.","startDate":"2026-07","conditions":"Lupus Nephritis (LN)","enrollment":24},{"nctId":"NCT06792552","phase":"PHASE1","title":"A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"NextCure, Inc.","startDate":"2025-02-26","conditions":"Advanced Solid Tumors","enrollment":414},{"nctId":"NCT06639256","phase":"PHASE1, PHASE2","title":"Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Sichuan Huiyu Pharmaceutical Co., Ltd","startDate":"2024-10-24","conditions":"Safety, Tolerability, Efficacy","enrollment":258},{"nctId":"NCT06814041","phase":"NA","title":"Pilot RCT and Interview Study on an HIV Chatbot in Nigeria","status":"ACTIVE_NOT_RECRUITING","sponsor":"Christoph Pimmer","startDate":"2025-04-14","conditions":"HIV","enrollment":314},{"nctId":"NCT05633654","phase":"PHASE3","title":"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-12-12","conditions":"Triple Negative Breast Cancer","enrollment":1514},{"nctId":"NCT05245968","phase":"PHASE1","title":"A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2021-12-01","conditions":"Gastrointestinal Stromal Tumors","enrollment":78},{"nctId":"NCT03652064","phase":"PHASE3","title":"A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-11-06","conditions":"Multiple Myeloma","enrollment":395},{"nctId":"NCT02969837","phase":"PHASE2","title":"Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2017-07-10","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT07346560","phase":"NA","title":"1ry Versus 2ry ILM Peeling in RD","status":"RECRUITING","sponsor":"Sohag University","startDate":"2025-12-15","conditions":"Retinal Detachment Rhegmatogenous, ILM Peeling","enrollment":100},{"nctId":"NCT05090865","phase":"NA","title":"Dietary Potassium Liberalization in Pre-Dialysis Patients","status":"RECRUITING","sponsor":"University of Manitoba","startDate":"2024-01-15","conditions":"Chronic Kidney Disease, Hyperkalemia","enrollment":30},{"nctId":"NCT07146516","phase":"NA","title":"Retinal Detachment Prevention (Laser Prophylaxis) in Stickler Syndrome (SS)","status":"RECRUITING","sponsor":"Helen Keller Eye Research Foundation","startDate":"2025-10-30","conditions":"Stickler Syndrome Type 1, Stickler Syndrome Type 2","enrollment":500},{"nctId":"NCT04471987","phase":"PHASE1","title":"Safety and Early Signs of Efficacy of IL12-L19L19.","status":"RECRUITING","sponsor":"Philogen S.p.A.","startDate":"2020-07-01","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":80},{"nctId":"NCT06640413","phase":"PHASE1","title":"A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors","status":"RECRUITING","sponsor":"Philogen S.p.A.","startDate":"2025-10-31","conditions":"FAP","enrollment":56},{"nctId":"NCT07329231","phase":"NA","title":"Quinoa Improves Glycolipid Metabolism and Glucose Fluctuation Based on β-Cell Function in Early-stage Type 2 Diabetes","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2021-01-10","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":60},{"nctId":"NCT07245992","phase":"PHASE1","title":"A Study of F8IL10 Intra-articular Treatment in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Philogen S.p.A.","startDate":"2026-01","conditions":"Rheumatoid Arthritis (RA)","enrollment":42},{"nctId":"NCT07327021","phase":"PHASE2","title":"MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC","status":"RECRUITING","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2025-11-11","conditions":"TNBC, Triple Negative Breast Cancer, Early Breast Cancer","enrollment":54},{"nctId":"NCT03702725","phase":"PHASE1","title":"Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2019-08-29","conditions":"Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma","enrollment":14},{"nctId":"NCT07068165","phase":"PHASE2, PHASE3","title":"A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-07-07","conditions":"IgG4 Related Disease","enrollment":198},{"nctId":"NCT04009005","phase":"NA","title":"Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Terry L. Wahls","startDate":"2020-05-01","conditions":"Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis","enrollment":44},{"nctId":"NCT04123418","phase":"PHASE1","title":"A Study of WVT078 in Patients With Multiple Myeloma (MM)","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-12-05","conditions":"Multiple Myeloma (MM)","enrollment":56},{"nctId":"NCT04294160","phase":"PHASE1","title":"A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-07-22","conditions":"BRAF V600 Colorectal Cancer","enrollment":122},{"nctId":"NCT06042725","phase":"PHASE1","title":"MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-03-04","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT07298590","phase":"EARLY_PHASE1","title":"An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related Disease","status":"NOT_YET_RECRUITING","sponsor":"Changhai Hospital","startDate":"2025-12-30","conditions":"IgG4 Related Disease","enrollment":18},{"nctId":"NCT07222553","phase":"PHASE2","title":"Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD","status":"NOT_YET_RECRUITING","sponsor":"Amgen","startDate":"2026-04-03","conditions":"Immunoglobulin G4-related Disease","enrollment":15},{"nctId":"NCT07265401","phase":"NA","title":"The Effect of Salutogenic Model-Based Care on Mothers of Children Suffering From Febrile Illness","status":"COMPLETED","sponsor":"Istanbul University - Cerrahpasa","startDate":"2023-10-01","conditions":"Mothers","enrollment":90},{"nctId":"NCT07262853","phase":"NA","title":"Dual Executive Function Training Package","status":"RECRUITING","sponsor":"Education University of Hong Kong","startDate":"2025-10-13","conditions":"ADHD, Dyslexia, Autism","enrollment":288},{"nctId":"NCT03829371","phase":"PHASE4","title":"STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Turin, Italy","startDate":"2019-01-03","conditions":"Multiple Myeloma","enrollment":450},{"nctId":"NCT05622175","phase":"PHASE1","title":"Safety and Preliminary Signs of Efficacy of F8IL10 for Intra-articular Treatment","status":"WITHDRAWN","sponsor":"Philogen S.p.A.","startDate":"2023-03-31","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT07259434","phase":"NA","title":"Time Restricted Eating in Survivors Trial 2.0","status":"NOT_YET_RECRUITING","sponsor":"University of Toronto","startDate":"2026-01-01","conditions":"Breast Cancer, Cardiovascular Risk, Cognitive Function","enrollment":152},{"nctId":"NCT04091126","phase":"PHASE1","title":"Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2019-12-18","conditions":"Multiple Myeloma","enrollment":118},{"nctId":"NCT03284957","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2017-09-20","conditions":"Breast Cancer","enrollment":136},{"nctId":"NCT06671613","phase":"NA","title":"Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2025-10-27","conditions":"Stage IV NSCLC, NSCLC, Immunotherapy","enrollment":66},{"nctId":"NCT06616766","phase":"PHASE1, PHASE2","title":"A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946","status":"RECRUITING","sponsor":"Yuhan Corporation","startDate":"2024-10-02","conditions":"NSCLC (Non-small Cell Lung Cancer), Solid Tumor","enrollment":161},{"nctId":"NCT06555965","phase":"","title":"STXBP1 and SYNGAP1 Related Disorders Natural History Study","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2023-08-30","conditions":"Genetic Disease, STXBP1 Encephalopathy With Epilepsy, SYNGAP1-Related Intellectual Disability","enrollment":600},{"nctId":"NCT04457596","phase":"PHASE3","title":"T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2021-03-02","conditions":"Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8","enrollment":1056},{"nctId":"NCT02252172","phase":"PHASE3","title":"Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-02-16","conditions":"Multiple Myeloma","enrollment":737},{"nctId":"NCT04520451","phase":"PHASE2","title":"Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants","status":"COMPLETED","sponsor":"Principia Biopharma, a Sanofi Company","startDate":"2020-08-22","conditions":"Immunoglobulin G4 Related Disease","enrollment":27},{"nctId":"NCT06752681","phase":"PHASE1","title":"To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Day One Biopharmaceuticals, Inc.","startDate":"2024-11-18","conditions":"Advanced or Metastatic Solid Tumors","enrollment":254},{"nctId":"NCT04810611","phase":"PHASE1","title":"Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-06-18","conditions":"Myelodysplastic Syndromes","enrollment":33},{"nctId":"NCT07207889","phase":"","title":"Retrospective Analysis of the Efficacy of Morphine Gel to Treat Pain Associated With Perineal RadioDermatitis","status":"COMPLETED","sponsor":"Institut Curie","startDate":"2024-12-01","conditions":"Dermatitis, Radiation Induced","enrollment":17},{"nctId":"NCT04562389","phase":"PHASE3","title":"Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2021-03-11","conditions":"Myelofibrosis","enrollment":353},{"nctId":"NCT05113641","phase":"NA","title":"Reducing Dietary Acid With Food Versus Oral Alkali in People With Chronic Kidney Disease (ReDACKD)","status":"RECRUITING","sponsor":"Dylan MacKay","startDate":"2023-08-04","conditions":"Chronic Kidney Diseases, Metabolic Acidosis","enrollment":40},{"nctId":"NCT04365569","phase":"NA","title":"Evaluating the Effectiveness of an Individualized Nutrition and Physical Activity Counseling Program","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2021-01-06","conditions":"Breast Cancer","enrollment":78},{"nctId":"NCT05145400","phase":"PHASE2","title":"Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2022-02-18","conditions":"Multiple Myeloma, Cancer","enrollment":50},{"nctId":"NCT06452654","phase":"PHASE4","title":"Anti-viral Action Against Type 1 Diabetes Autoimmunity","status":"RECRUITING","sponsor":"Technical University of Munich","startDate":"2024-05-08","conditions":"Diabetes Mellitus, Type 1","enrollment":2252},{"nctId":"NCT07187167","phase":"PHASE2","title":"Efficacy and Safety of the RD Regimen(Lenalidomide, Dexamethasone) for Rosai-Dorfman Disease","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-04-12","conditions":"Rosai-Dorfman Disease","enrollment":40},{"nctId":"NCT03929666","phase":"PHASE2","title":"A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2019-08-29","conditions":"HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer","enrollment":74},{"nctId":"NCT02414126","phase":"NA","title":"Evaluation of Breathing, Sleep and the Effects of Continuous Positive Airway Pressure During Wakefulness in Children With Heart Failure","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-07-10","conditions":"Heart Failure","enrollment":30},{"nctId":"NCT03993912","phase":"PHASE3","title":"Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Lille","startDate":"2019-10-17","conditions":"Multiple Myeloma","enrollment":294},{"nctId":"NCT03004287","phase":"PHASE2","title":"2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2017-07-01","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT06235684","phase":"","title":"Clinnova-RD: A Prospective Cohort Study of Patients With Rheumatoid Diseases","status":"NOT_YET_RECRUITING","sponsor":"Luxembourg Institute of Health","startDate":"2026-04-01","conditions":"Rheumatoid Diseases","enrollment":100},{"nctId":"NCT07158073","phase":"NA","title":"Effect of ORI-guided Oxygen Titration on Oxidative Stress in Rhinoplasty Surgery","status":"COMPLETED","sponsor":"Dr. Lutfi Kirdar Kartal Training and Research Hospital","startDate":"2021-03-01","conditions":"Rhinoplasty, Oxidative Stress, Hyperoxia","enrollment":60},{"nctId":"NCT07155512","phase":"NA","title":"Impact of a Bespoke Mindfulness Intervention for Registered Dietitians on Resilience, Burnout and Stress","status":"COMPLETED","sponsor":"University of Nottingham","startDate":"2024-03-08","conditions":"Resilience, Psychological, Burnout, Professional, Stress, Psychological","enrollment":30},{"nctId":"NCT07148791","phase":"PHASE2","title":"Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-09-05","conditions":"IgG4 Related Disease, B-cell Mediated Autoimmune Disorders","enrollment":9},{"nctId":"NCT07141862","phase":"","title":"Fertility Preservation in Children With Solid Tumors: Detection of Residual Disease by a Sensitive Method","status":"RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2025-02-01","conditions":"Neuroblastoma, Ewing Sarcoma","enrollment":89},{"nctId":"NCT06377501","phase":"NA","title":"Feasibility of a Whole-Food, Plant-Based Diet for Patients With Low-Risk Chronic Lymphocytic Leukemia (CLL)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2023-03-07","conditions":"Chronic Lymphocytic Leukemia Stage A(0)","enrollment":19},{"nctId":"NCT07140029","phase":"","title":"Comparative Clinical Study of Intraocular Lens Injectors Lioli™, Pioli™, and Pioli™ Plus","status":"RECRUITING","sponsor":"AST Products, Inc.","startDate":"2025-08","conditions":"Cataract, Lens Implantation, Intraocular","enrollment":120},{"nctId":"NCT06952478","phase":"PHASE3","title":"A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma","status":"RECRUITING","sponsor":"Celltrion","startDate":"2025-08-12","conditions":"Refractory or Relapsed Multiple Myeloma","enrollment":486},{"nctId":"NCT07125040","phase":"","title":"Characterization of the Natural History of LAMA2-RD and Identification of Novel Disease Biomarkers","status":"RECRUITING","sponsor":"Università Vita-Salute San Raffaele","startDate":"2025-07-31","conditions":"LAMA2-MD (Merosin Deficient Congenital Muscular Dystrophy, MDC1A), LAMA2-MD \\(Merosin Deficient Congenital Muscular Dystrophy, MDC1A\\), Merosin Deficient CMD (Full or Partial)","enrollment":45},{"nctId":"NCT02795195","phase":"PHASE1, PHASE2","title":"Trail Evaluating Carbon Ion Radiotherapy (3 GyE Per Fraction) for Locally Recurrent Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Shanghai Proton and Heavy Ion Center","startDate":"2016-01","conditions":"Nasopharyngeal Carcinoma","enrollment":51},{"nctId":"NCT07104058","phase":"NA","title":"A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD","status":"RECRUITING","sponsor":"Luo Yaping","startDate":"2025-05-10","conditions":"IgG4-Related Diseases","enrollment":46},{"nctId":"NCT06975410","phase":"PHASE1, PHASE2","title":"Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors","status":"RECRUITING","sponsor":"Yuhan Corporation","startDate":"2025-06-12","conditions":"EGFR Overexpression, Locally Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":80},{"nctId":"NCT06465693","phase":"NA","title":"Personalized Nutrition Therapy Using Continuous Glucose Monitoring to Improve Outcomes in Type 2 Diabetes Mellitus","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Minnesota","startDate":"2024-05-01","conditions":"Type 2 Diabetes","enrollment":8},{"nctId":"NCT06087133","phase":"NA","title":"Prenatal Starting Early Program mHealth","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2023-12-08","conditions":"Pregnancy","enrollment":276},{"nctId":"NCT05977179","phase":"NA","title":"Dietary Intervention to Mitigate Post-Acute COVID-19 Syndrome","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2025-05-12","conditions":"Post-Acute COVID-19 Syndrome, Fatigue","enrollment":56},{"nctId":"NCT00624234","phase":"NA","title":"Neurobiology and Treatment of Reading Disability in NF-1","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2006-02","conditions":"Neurofibromatosis Type 1, Reading Disabilities","enrollment":184},{"nctId":"NCT07052747","phase":"","title":"Periodontal Effects of Orthodontic Mini-Screws","status":"COMPLETED","sponsor":"Dr. Mehmet Selim Yildiz","startDate":"2024-10-04","conditions":"Dental Implantation, Peri-implant Mucositis, Orthodontic Anchorage Procedures","enrollment":132},{"nctId":"NCT03248492","phase":"PHASE2","title":"A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)","status":"TERMINATED","sponsor":"Daiichi Sankyo","startDate":"2017-08-25","conditions":"Breast Cancer","enrollment":253},{"nctId":"NCT03479736","phase":"","title":"A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-20","conditions":"Retinal Detachment, Achilles Tendon, Aneurysm, Dissecting","enrollment":117911},{"nctId":"NCT07037368","phase":"","title":"Impact of Delivery Mode on Coccydynia, Pelvic Girdle Pain and Rectus Diastasis in Postpartum Females","status":"ACTIVE_NOT_RECRUITING","sponsor":"Superior University","startDate":"2025-03-04","conditions":"Pelvic Girdle Pain, Rectus Diastasis","enrollment":73},{"nctId":"NCT02964884","phase":"PHASE2","title":"Interventions for Reading Disabilities in NF1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University","startDate":"2016-11","conditions":"Neurofibromatosis Type 1, Learning Disability, Reading Disability","enrollment":120},{"nctId":"NCT06785324","phase":"NA","title":"Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-05-12","conditions":"Philadelphia Chromosome Negative, B Cell Acute Lymphoblastic Leukemia (B-ALL), B-ALL","enrollment":20},{"nctId":"NCT07013526","phase":"NA","title":"Dexmedetomidine as Adjuvant for Suprazygomatic Maxillary Nerve Block in Children's Adenotonsillectomy","status":"NOT_YET_RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2025-09-01","conditions":"Adenotonsillectomy","enrollment":150},{"nctId":"NCT06230510","phase":"NA","title":"Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2024-08-15","conditions":"Obesity","enrollment":625},{"nctId":"NCT06149416","phase":"NA","title":"SpO2 Accuracy of Noninvasive Pulse Oximeter Sensor With Motion Conditions","status":"COMPLETED","sponsor":"Stryker Sustainability Solutions","startDate":"2023-05-27","conditions":"Healthy, Hypoxia","enrollment":11},{"nctId":"NCT04358237","phase":"PHASE1, PHASE2","title":"Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.","status":"COMPLETED","sponsor":"Antonio Calles Blanco","startDate":"2020-09-21","conditions":"Small Cell Lung Carcinoma","enrollment":28}],"_emaApprovals":[],"_faersSignals":[{"count":59,"reaction":"AGRANULOCYTOSIS"},{"count":45,"reaction":"LEUKOPENIA"},{"count":20,"reaction":"BONE MARROW FAILURE"},{"count":17,"reaction":"GENERAL PHYSICAL HEALTH DETERIORATION"},{"count":17,"reaction":"PNEUMONIA"},{"count":14,"reaction":"ACUTE KIDNEY INJURY"},{"count":14,"reaction":"SOMNOLENCE"},{"count":13,"reaction":"TOXICITY TO VARIOUS AGENTS"},{"count":12,"reaction":"ACCIDENTAL DEATH"},{"count":12,"reaction":"CARDIAC FAILURE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lenalidomide +Dexamethasone"],"phase":"marketed","status":"active","brandName":"Rd","genericName":"Rd","companyName":"Ascentage Pharma Group Inc.","companyId":"ascentage-pharma-group-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rd is a BCL-2 family protein inhibitor that promotes apoptosis in cancer cells by blocking anti-apoptotic proteins. Used for Hematologic malignancies (specific indications pending confirmation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}